Pfizer's controlled-release Lyrica fails in Phase III
This article was originally published in Scrip
Executive Summary
A Phase III trial investigating a controlled-release (CR) formulation of Pfizer's GABA analogue pregabalin as an adjunctive treatment in adult patients with partial onset seizures, caused by epilepsy, has failed to meet its primary endpoint, according to top-line results.